SCHEMBL29387299

SCHEMBL29387299

FC(F)(F)CN1CCC2(CC1)CNc1ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRNP P04156 1/20 0.44
TNKS O95271 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
CCR5 P51681 1/20 0.41
AVPR1A P37288 1/20 0.39
OPRM1 P35372 4/20 0.38
OPRK1 P41145 2/20 0.38
OPRD1 P41143 1/20 0.38
KCNH2 Q12809 1/20 0.37
HDAC1 Q13547 1/20 0.37
OPRL1 P41146 3/20 0.36
SIGMAR1 Q99720 7/20 0.34
TP53 P04637 3/20 0.34
CYP3A4 P08684 3/20 0.34
TSHR P16473 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C19 P33261 2/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2259734 1.00 PRNP (0.44) PRNPTNKSTNKS2CCR5AVPR1A
SCHEMBL25422388 0.92 PRNP (0.41) PRNPTNKSTNKS2CCR5AVPR1A
SCHEMBL25425006 0.92 PRNP (0.41) PRNPTNKSTNKS2CCR5AVPR1A
SCHEMBL26969783 0.87 KDM1A (0.39) PRNPTNKSTNKS2OPRM1OPRK1
SCHEMBL29386692 0.87 KDM1A (0.39) PRNPTNKSTNKS2OPRM1OPRK1
SCHEMBL1572043 0.86 TNKS (0.41) PRNPTNKSTNKS2CCR5AVPR1A
SCHEMBL12715975 0.81 TNKS (0.44) PRNPTNKSTNKS2CCR5AVPR1A
SCHEMBL2109397 0.81 TNKS (0.44) PRNPTNKSTNKS2CCR5AVPR1A
SCHEMBL12716046 0.81 TNKS (0.44) PRNPTNKSTNKS2CCR5AVPR1A
SCHEMBL4266427 0.79 TNKS (0.46) PRNPTNKSTNKS2CCR5AVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416262-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-12-28 US disclosed
EP-4192957-A2 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2023-06-14 EP disclosed
WO-2022032073-A2 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416262-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 PRNP 3576/4885TNKS 2035/4885TNKS2 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.